Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 15/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23245435 | 1.00 | USP30 (0.45) | USP30NR1H2NR1H3CCNB2CDK1 | |
| SCHEMBL1621434 | 0.89 | NR1H2 (0.43) | NR1H2NR1H3CCNB2CDK1CCNB1 | |
| SCHEMBL17433471 | 0.84 | USP30 (0.44) | USP30NR1H2NR1H3CCNB2CDK1 | |
| SCHEMBL17673158 | 0.84 | USP30 (0.44) | USP30NR1H2NR1H3CCNB2CDK1 | |
| SCHEMBL13515283 | 0.83 | AKR1C3 (0.40) | NR1H2NR1H3CCR9CA12CA9 | |
| SCHEMBL15727386 | 0.82 | USP30 (0.43) | USP30NR1H2NR1H3CCNB2CDK1 | |
| SCHEMBL27247821 | 0.82 | USP30 (0.47) | USP30NR1H2NR1H3CCNB2CDK1 | |
| SCHEMBL27112009 | 0.82 | NR1H2 (0.44) | USP30NR1H2NR1H3CCNB2CDK1 | |
| SCHEMBL12685163 | 0.82 | NR1H2 (0.49) | NR1H2CCR9 | |
| SCHEMBL15232770 | 0.82 | NR1H2 (0.40) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319698-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11560385-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560385-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | USP30 52/4885NR1H2 1689/4885NR1H3 2195/4885 |
| US-12319698-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | USP30 52/4885NR1H2 1689/4885NR1H3 2195/4885 |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | USP30 52/4885NR1H2 1689/4885NR1H3 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.